All In Biotech

Drug Trial Radar · NCT03538691

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,149

Actual

Start

Jul 13, 2018

Primary completion

Jul 8, 2022

Study completion Jul 29, 2022

Sponsor

Sponsor type
Industry
First posted
May 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging. This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.

Conditions

  • Major Depressive Disorder

Interventions

  • BrexpiprazoleDrug

    Administered as tablets.

  • Antidepressant therapyDrug

    Protocol-specified oral ADTs included: citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded AddendumTime frame: Up to 14 days post last dose in Phase C (up to 28 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding sites, contact 844-687-8522

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.